Postprandial Hypertriglyceridaemia Revisited In The Era Of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement.

Postprandial Hypertriglyceridaemia Revisited In The Era Of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement. Curr Vasc Pharmacol. 2019 May 07;: Authors: Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG Abstract Residual vascular risk exists despite aggressive lowering of low density lipoprotein cholesterol (LDL-C). A contributor to this residual risk may be elevated fasting, or non-fasting, levels of triglyceride (TG)-rich lipoproteins. Therefore, there is a need to establish whether a standardised oral fat tolerance test (OFTT) can improve atherosclerotic cardiovascular (CV) disease (ASCVD) risk prediction in addition to a fasting or non-fasting lipid profile. An expert panel considered the role of postprandial hypertriglyceridaemia (as represented by an OFTT) in predicting ASCVD. The panel updated its 2011 statement by considering new studies and various patient categories. The recommendations are based on expert opinion since no hard endpoint trials have been performed, Table 1. Individuals with fasting TG concentration <1 mmol/L (89 mg/dL) commonly do not have an abnormal response to an OFTT. In contrast, those with fasting TG concentration ≥2 mmol/L (175 mg/dL) or non-fasting ≥2.3 mmol/L (200 mg/dL) will usually have an abnormal response. We recommend considering postprandial h...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research